abrdn Life Sciences Investors Fund maintains a buy rating, offering a compelling 11.6% yield and trading at a 9.58% NAV discount. HQL’s income-focused strategy relies on net realized gains, supporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results